Leonard T Heffner Jr
Overview
Explore the profile of Leonard T Heffner Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roberts MMSc D, Langston A, Heffner Jr L
J Oncol Pract
. 2019 Jun;
15(6):315-320.
PMID: 31185191
With the exception of the minority of patients with acute myelocytic leukemia who are considered potentially cured by chemotherapy, hematopoietic cell transplantation (HCT) has traditionally been the recommended approach for...
2.
Jagannath S, Heffner Jr L, Ailawadhi S, Munshi N, Zimmerman T, Rosenblatt J, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Apr;
19(6):372-380.
PMID: 30930134
Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. Patients And Methods: We report from 2 clinical studies of...
3.
Matulis S, Gupta V, Neri P, Bahlis N, Maciag P, Leverson J, et al.
Leukemia
. 2019 Jan;
33(5):1291-1296.
PMID: 30679802
No abstract available.
4.
Barbee M, Nooka A, Kaufman J, Kim S, Chen Z, Heffner Jr L, et al.
Cancer
. 2014 Nov;
121(6):853-62.
PMID: 25377852
Background: The categories of the International Myeloma Working Group (IMWG) response criteria for multiple myeloma are based on the magnitude of the change in paraprotein and the normalization of the...
5.
Sinha R, Shenoy P, King N, Lechowicz M, Bumpers K, Hutcherson D, et al.
Clin Lymphoma Myeloma Leuk
. 2013 Oct;
13(6):657-63.
PMID: 24094894
Background: For Hodgkin lymphoma (HL) patients with refractory or relapsed (R/R) disease after primary therapy, the standard of care is a salvage regimen followed by autologous stem cell transplant (ASCT)....
6.
Antun A, Gleason S, Arellano M, Langston A, McLemore M, Gaddh M, et al.
Cancer
. 2013 Aug;
119(21):3784-7.
PMID: 23921838
Background: Despite prophylactic platelet transfusions, bleeding remains a significant problem in thrombocytopenic patients. Methods: The antifibrinolytic agent epsilon aminocaproic acid (EACA) was administered to 44 chronically (median duration, 273 days)...
7.
Brinker B, Waller E, Leong T, Heffner Jr L, Redei I, Langston A, et al.
Cancer
. 2006 Apr;
106(10):2171-80.
PMID: 16598756
Background: High-dose chemotherapy with autologous hematopoietic progenitor cell (HPC) transplantation improves survival for patients with multiple myeloma (MM); however, most patients develop recurrent disease after undergoing transplantation, and new treatment...
8.
Heffner Jr L, Lonial S
Drugs
. 2003 Aug;
63(16):1621-36.
PMID: 12904084
Although multiple myeloma remains a terminal illness, the past four decades have seen a dramatic change in the outlook for a newly diagnosed patient in terms of therapies available, supportive...